Monopar Therapeutics Stock Surges on Clinical Progress and Analyst Optimism

Shares of Monopar Therapeutics experienced a significant rally, propelled by encouraging clinical trial developments and a wave of positive analyst coverage. The biotech firm’s stock posted notable gains in the latest trading session.

Strong Analyst Sentiment Drives Momentum

A series of new analyst initiations has generated considerable market enthusiasm for Monopar. The consensus view is overwhelmingly bullish, with multiple firms issuing positive ratings and substantial price targets.

• Raymond James commenced coverage with a Strong Buy rating and an $80 price objective.
• Oppenheimer initiated coverage with an Outperform recommendation and a $77 target, highlighting the drug’s differentiated mechanism of action.
• Cantor Fitzgerald reaffirmed its Overweight stance with a $74 price target.
• HC Wainwright started coverage with a Buy rating and a $70 target.
• Chardan Capital maintained its Buy recommendation with a $60 target.

The average price target from six analysts stands at $82.33, implying a potential upside of over 125% from the previous closing price. The consensus recommendation is Outperform.

Key Clinical Milestone for Wilson’s Disease Program

The catalyst for this increased attention is a significant development in Monopar’s clinical pipeline. The company announced that an abstract for ALXN1840, its investigational therapy for Wilson’s disease, has been selected for both an oral and a poster presentation at the upcoming annual congress of the American Neurological Association.

Should investors sell immediately? Or is it worth buying Monopar Therapeutics?

This prestigious recognition underscores the scientific merit of the data, which demonstrates long-term improvement in neurological symptoms. The complete dataset is scheduled for publication in mid-September. This progress is critical as Monopar targets an early 2026 New Drug Application (NDA) submission to the FDA for ALXN1840, a major step toward potential market approval.

Market Response and Financial Health

The market’s reaction to these developments was immediate and forceful. The stock price advanced 6.72% yesterday, climbing from $33.93 to $36.21. This upward move was accompanied by a surge in trading activity, with volume increasing by 29,000 shares to reach a total of 60,000 shares traded—a clear indicator of robust buyer interest.

The company’s financial position provides a solid foundation for its ongoing operations. With $53.3 million in cash and liquid assets, Monopar is funded through at least the end of 2026. This capital is expected to support the preparation of the NDA and the continued advancement of its radiopharmaceutical programs. For the second quarter of 2025, the company reported a net loss of $2.5 million, or $0.35 per share, an improvement compared to a net loss of $1.7 million, or $0.49 per share, in the same period last year.